Systematic Review or Meta Analysis

Accurate diagnosis and classification affect treatment choices and risks—misdiagnosis can lead to unnecessary immunosuppression, while misclassification can under-recognize severe or proximal disease that needs different...

Definitions of "disease burden" vary a lot, which makes it hard to compare studies or to ensure care and research address what matters most to people with Crohn's. A unified, multidimensional framework could help...

People with IBD and coexisting primary sclerosing cholangitis (PSC) are at higher colorectal neoplasia risk and may respond differently to IBD medicines. This meta-analysis compiles available evidence on commonly used...

People with PSC who undergo liver transplant — especially those who have IBD at the time of transplant — remain at elevated risk for colorectal neoplasia, IBD flare or new-onset IBD, and for PSC recurrence. Knowing this...

If endometriosis is linked to other immune, allergic, or chronic pain conditions, people with endometriosis may benefit from broader evaluation and coordinated care beyond gynecology. The review suggests shared...

Perianal fistulizing Crohn's disease is a frequent, hard-to-treat complication; molecular and multiomic advances could lead to biomarkers that help choose better-targeted therapies and improve surgical–medical decision...

Pyroptosis is a key inflammatory pathway that may drive or modulate IBD activity. Understanding and targeting it could lead to new treatments, but past trial setbacks mean patients should know translation is still...

The review identifies PPARγ as a key molecular hub in ulcerative colitis and compiles preclinical evidence that natural compounds can modulate PPARγ-related networks—suggesting possible new therapeutic directions that...

Families and clinicians often wonder whether H. pylori infection in childhood affects risks for asthma, IBD, celiac disease, or other immune-mediated disorders.

This review compiles preclinical evidence that propolis (a natural bee product) reduced inflammation and improved gut barrier and microbiota in animal models of colitis, so it may be a candidate for future clinical...

Multi-omics and AI approaches could improve biomarker discovery and predictive models that matter for earlier diagnosis and personalised treatment strategies in IBD, but practical use is limited today by data and...

This review summarizes how ulcerative colitis trials have been designed recently and flags common weaknesses (small samples, short follow-up, overreliance on Mayo score). Better-designed trials could produce results that...

Nutritional disorders in IBD (underweight/malnutrition, overweight/obesity, and muscle loss/sarcopenia) are common and affect treatment tolerance, recovery, and quality of life. Knowing how frequent these problems are...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease, Infliximab, and Anti-TNF. The original article is from Current Gastroenterology...

Patients and clinicians use the term "disease burden" to describe more than inflammation alone; it affects symptoms, daily function, mental health, and healthcare use. A clearer, integrated way to measure burden could...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Crohn's disease, Inflammatory bowel disease, and Biomarkers. The original article is from Frontiers in medicine.

Capsaicin is commonly consumed and acts on TRPV1, which is increased in inflamed IBD tissue; depending on dose and disease activity it may help or worsen inflammation and symptom-related pain.

MMP-2 regulates tissue remodeling and inflammation in IBD; targeting it might help prevent barrier damage, chronic inflammation, or fibrosis but requires selective approaches to avoid harming normal repair processes.

The review links ER stress and mitochondrial dysfunction to core IBD processes (inflammation, barrier damage, cell death) and highlights MERCs as an integrated signaling hub, suggesting new biomarker and therapeutic...

Noninvasive imaging that better separates inflammation from fibrosis and detects penetrating complications could change monitoring and treatment decisions in IBD and reduce radiation exposure for patients needing...

The analysis helps compare multiple advanced therapies when head‑to‑head trials are lacking, which may inform drug selection for induction and maintenance in moderate‑to‑severe UC, including for patients who have failed...

This review addresses whether people with IBD face higher breast cancer risk and how treatments for one disease might affect the other—questions many patients and clinicians raise when cancer and IBD overlap.

Researchers are exploring new oral delivery carriers that could deliver drugs directly to inflamed intestinal sites while also modulating immune responses and the gut microbiome. If translated, these approaches might...

The review links microbiome, metabolites, barrier function, and immune responses across anorectal disorders and ulcerative colitis — areas that directly affect symptoms, healing, and response to therapy.

People with IBD often ask about dietary supplements. This systematic review suggests some randomized-trial evidence that polyphenol supplements—especially curcumin—may help induce clinical improvement in ulcerative...

AMNs are rare but can be malignant and may mimic UC flares or appendicitis, which can delay diagnosis. For people with long-standing UC, awareness may prompt appropriate imaging and surgical referral.

Enteric hyperoxaluria increases risk of calcium oxalate kidney stones and kidney injury. Knowing how common EH is in Crohn's disease and after bariatric surgery helps identify who might benefit from screening and...

This paper maps where and how mitochondria-related IBD research has grown and what themes (like mitophagy, metabolism, and machine learning) are emerging — useful for researchers, funders, and clinicians tracking...

This review directly addresses whether switching from originator infliximab to a biosimilar affects disease control or safety in children with IBD — a common practical concern for families and clinicians. Its pooled data...

The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...

Families and clinicians deciding on a first biologic for a child with ulcerative colitis need to know which drugs have pediatric-specific evidence. This review shows infliximab has the strongest pediatric data, while...

If you or your child is starting exclusive enteral nutrition (EEN) for pediatric Crohn’s disease, this review explains why outcomes vary and what tests and research might help predict who will benefit.

Up to one-third of people with IBD in clinical remission still have IBS-like symptoms that reduce quality of life and are not helped by anti-inflammatory treatments.

People with IBD often have sleep problems and ongoing inflammation; melatonin could help both sleep and clinical disease activity, which may improve quality of life. The review suggests potential benefit but is not...

If true, the tripartite circuit model helps explain why some patients respond to therapies that target one pathway while others do not — because other nodes in the loop may sustain disease.

Detecting molecular signs of IBD before symptoms could eventually allow earlier monitoring or preventive strategies, changing how and when people at risk are identified. For patients, this research points to hope that...

A subcutaneous option for infliximab could simplify maintenance therapy, reduce infusion visits, and change how drug levels and accompanying immunomodulators are managed — issues many people with IBD and their clinicians...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Crohn's disease, Inflammatory bowel disease, and Microbiome. The original article is from Immunity, inflammation...

This review summarises the rapidly changing drug landscape for Crohn’s disease and ulcerative colitis, including newly approved biologics and small molecules and several emerging therapies that may affect future...

Accurate, radiation-free imaging at the point of care can speed diagnosis and management of strictures, abscesses, and fistulas in Crohn’s disease. Improved ultrasound techniques may help determine who needs surgery or...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease, Crohn's disease, and Biosimilars. The original article is from Arquivos de...

Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease and Research and clinical trials. The original article is from Journal of inflammation...

Berries are a familiar, dietary source of anti-inflammatory bioactive compounds that might help reduce intestinal inflammation and improve biomarkers relevant to IBD. Patients often seek safe, complementary strategies...

Curcumin is a common dietary compound that reaches the colon and may interact with gut bacteria and host immune and barrier pathways implicated in IBD. Understanding these interactions could inform dietary approaches or...

The review links TCM-derived compounds to mechanisms (microbiota, metabolites, immunity) that are implicated in progression from chronic colitis to colorectal cancer, which is an important long-term risk for people with...

People with Crohn’s disease may see emerging interest in traditional Chinese medicine as a multi-target approach that could complement standard treatments and affect immune pathways, the gut barrier, and the microbiome.

Localized hydrogel drug delivery aims to concentrate therapy at inflamed gut sites while reducing systemic side effects — a potentially useful approach for people with IBD who have inadequate response or intolerable...

People with IBD often hear about “treat-to-target” as a path to deeper healing.